News | April 01, 2014

Frost & Sullivan Recognizes Sensus for Development of Low-Energy Radiotherapy Systems for Skin Cancer

Products have demonstrated safety, clinical efficacy and potential for widespread adoption to treat dermatological and oncological conditions, says analyst

April 1, 2014 — Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognized Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100 and SRT-100 Vision.

Competing products use electron beams ranging from 1 to 12 mega electron volts (MeV), or decaying isotope-based emitting sources. Patients are typically subjected to radiation levels many times the energy required for non-melanoma skin cancer treatment, with only a part of the energy being delivered to the surface of the skin. The SRT-100 and SRT-100 Vision use kilovoltage X-rays in the 50 to 100 kilo volts (KV) energy range. The radiation is delivered completely to the surface of the skin, without affecting the underlying healthy tissue and cells. SRT is ideal for irradiating tumorous growths at depths of between 0.5 mm and 5 mm.

The systems are small footprint and portable devices, similar in size and design to an ultrasound instrument. The SRT-100 Vision integrates high-resolution ultrasound imaging and laser positioning capabilities to help with the accurate localization, characterization and topology of lesions. This, in turn, will ensure optimal energy dosage, treatment fractionation and depth of beam penetration.

"SRT-100 and SRT-100 Vision utilize a noninvasive approach that does not leave scars and therefore eliminates the need for additional follow-up procedures, such as skin grafting and cosmetic reconstructive surgeries," said Frost & Sullivan Research Analyst Bhargav Rajan. "There is no loss of skin and/or sensation, and since it is a non-contact procedure, it is painless. The entire procedure lasts only seconds for each treatment fraction, compared to surgeries and other procedures, which take hours and additional recovery time."

A retrospective assessment of more than 1,700 patients who were treated for basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) using SRT-100 showed a 98 percent cure rate over two years, and a more than 95 percent cure rate over five years. These remarkable cure rates are comparable with those obtained using current clinical standards.

"SRT-100 has come to be considered medically necessary and/or an adjunctive procedure for the treatment of non-melanoma skin cancers and non-oncological skin conditions such as keloids," said Rajan. "Due to its record for safety, efficacy and low risks, it is covered by most insurance companies and Medicare for oncological and non-oncological procedures."

The U.S. Food and Drug Administration (FDA) recently granted 510(k) clearance to the SRT-100 for treating keloids (collagen-based non-malignant scars). With this regulatory approval, SRT-100 and SRT-100 Vision can now be used to treat non-oncological conditions (keloids) and pre-oncological conditions such as actinic keratosis.

For more information: www.frost.com

Related Content

News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
Designed to support a broad range of planning and delivery technologies, SunCheck 2.0 streamlines and standardizes workflows, allowing greater overall focus on patient safety.
Technology | Quality Assurance (QA) | April 27, 2018
Sun Nuclear Corp. released significant new functionality for its SunCheck Platform for patient and machine quality...
RayStation Users Win Inaugural Treatment Planning World Championships
News | Treatment Planning | April 27, 2018
In the first World Championships of Treatment Planning, arranged by radiation oncology analytics company ProKnow and...
Brainlab Introduces New Hi-Res Planning Algorithm for VersaHD
News | Treatment Planning | April 24, 2018
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around...
Shorter Radiotherapy Courses Safe and Effective for Prostate Cancer
News | Prostate Cancer | April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients,...
Elekta Expands Mosaiq Oncology Information System With PalabraApps
News | Oncology Information Management Systems (OIMS) | April 20, 2018
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the developm
This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
Overlay Init